The somatic mutational landscape and role of the ARID1A gene in hepatocellular carcinoma
Introduction: Hepatocellular carcinoma (HCC) is one of the most common malignant tumours worldwide. Clarification of the somatic mutational landscape of important genes could reveal new therapeutic targets and facilitate individualized therapeutic approaches for HCC patients. The mutation and expres...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-03-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023015141 |
| _version_ | 1797851800632557568 |
|---|---|
| author | Guang-Xiao Meng Chun-Cheng Yang Lun-Jie Yan Ya-Fei Yang Yu-Chuan Yan Jian-Guo Hong Zhi-Qiang Chen Zhao-Ru Dong Tao Li |
| author_facet | Guang-Xiao Meng Chun-Cheng Yang Lun-Jie Yan Ya-Fei Yang Yu-Chuan Yan Jian-Guo Hong Zhi-Qiang Chen Zhao-Ru Dong Tao Li |
| author_sort | Guang-Xiao Meng |
| collection | DOAJ |
| description | Introduction: Hepatocellular carcinoma (HCC) is one of the most common malignant tumours worldwide. Clarification of the somatic mutational landscape of important genes could reveal new therapeutic targets and facilitate individualized therapeutic approaches for HCC patients. The mutation and expression changes in the ARID1A gene in HCC remain controversial. Methods: First, cBioPortal was used to visualize genetic alterations and DNA copy number alterations (CNAs) in ARID1A. The relationships between ARID1A mutation status and HCC patient clinicopathological features and overall survival (OS) were also determined. Then, a meta-analysis was performed to evaluate the effect of ARID1A mutation or expression on the prognosis of HCC patients. Finally, the role of ARID1A in HCC progression was verified by in vitro experiments. Results: ARID1A mutation was detected in 9.35% (33/353) of sequenced HCC cases, and ARID1A mutation decreased ARID1A mRNA expression. Patients with ARID1A alterations presented worse OS than those without ARID1A alterations. Meta-analysis and human HCC tissue microarray (TMA) analysis revealed that HCC patients with low ARID1A expression had worse OS and relapse-free survival (RFS), and low ARID1A expression was negatively correlated with tumour size. Then, ARID1A gain-of-function and loss-of-function experiments demonstrated the tumour suppressor role of ARID1A in HCC in vitro. In terms of the mechanism, we found that ARID1A could inhibit HCC progression by regulating retinoblastoma-like 1 (RBL1) expression via the JNK/FOXO3 pathway. Conclusions: ARID1A can be considered a potential prognostic biomarker and candidate therapeutic target for HCC. |
| first_indexed | 2024-04-09T19:23:41Z |
| format | Article |
| id | doaj.art-b1864cd1c08e4c83a6bd7d6efd0983f4 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-04-09T19:23:41Z |
| publishDate | 2023-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-b1864cd1c08e4c83a6bd7d6efd0983f42023-04-05T08:23:03ZengElsevierHeliyon2405-84402023-03-0193e14307The somatic mutational landscape and role of the ARID1A gene in hepatocellular carcinomaGuang-Xiao Meng0Chun-Cheng Yang1Lun-Jie Yan2Ya-Fei Yang3Yu-Chuan Yan4Jian-Guo Hong5Zhi-Qiang Chen6Zhao-Ru Dong7Tao Li8Department of General Surgery, Qilu Hospital of Shandong University, Jinan, 250012, China; Laboratory of Basic Medical Sciences, Qilu Hospital of Shandong University, Jinan, 250012, ChinaDepartment of General Surgery, Qilu Hospital of Shandong University, Jinan, 250012, China; Laboratory of Basic Medical Sciences, Qilu Hospital of Shandong University, Jinan, 250012, ChinaDepartment of General Surgery, Qilu Hospital of Shandong University, Jinan, 250012, China; Laboratory of Basic Medical Sciences, Qilu Hospital of Shandong University, Jinan, 250012, ChinaDepartment of General Surgery, Qilu Hospital of Shandong University, Jinan, 250012, China; Laboratory of Basic Medical Sciences, Qilu Hospital of Shandong University, Jinan, 250012, ChinaDepartment of General Surgery, Qilu Hospital of Shandong University, Jinan, 250012, China; Laboratory of Basic Medical Sciences, Qilu Hospital of Shandong University, Jinan, 250012, ChinaDepartment of General Surgery, Qilu Hospital of Shandong University, Jinan, 250012, ChinaDepartment of General Surgery, Qilu Hospital of Shandong University, Jinan, 250012, ChinaDepartment of General Surgery, Qilu Hospital of Shandong University, Jinan, 250012, China; Corresponding author. Department of General Surgery Qilu Hospital, Shandong University Jinan, China.Department of General Surgery, Qilu Hospital of Shandong University, Jinan, 250012, China; Department of Hepatobiliary Surgery, The Second Hospital of Shandong University, Jinan, 250000, China; Corresponding author. Department of General Surgery Qilu Hospital, Shandong University Jinan, China.Introduction: Hepatocellular carcinoma (HCC) is one of the most common malignant tumours worldwide. Clarification of the somatic mutational landscape of important genes could reveal new therapeutic targets and facilitate individualized therapeutic approaches for HCC patients. The mutation and expression changes in the ARID1A gene in HCC remain controversial. Methods: First, cBioPortal was used to visualize genetic alterations and DNA copy number alterations (CNAs) in ARID1A. The relationships between ARID1A mutation status and HCC patient clinicopathological features and overall survival (OS) were also determined. Then, a meta-analysis was performed to evaluate the effect of ARID1A mutation or expression on the prognosis of HCC patients. Finally, the role of ARID1A in HCC progression was verified by in vitro experiments. Results: ARID1A mutation was detected in 9.35% (33/353) of sequenced HCC cases, and ARID1A mutation decreased ARID1A mRNA expression. Patients with ARID1A alterations presented worse OS than those without ARID1A alterations. Meta-analysis and human HCC tissue microarray (TMA) analysis revealed that HCC patients with low ARID1A expression had worse OS and relapse-free survival (RFS), and low ARID1A expression was negatively correlated with tumour size. Then, ARID1A gain-of-function and loss-of-function experiments demonstrated the tumour suppressor role of ARID1A in HCC in vitro. In terms of the mechanism, we found that ARID1A could inhibit HCC progression by regulating retinoblastoma-like 1 (RBL1) expression via the JNK/FOXO3 pathway. Conclusions: ARID1A can be considered a potential prognostic biomarker and candidate therapeutic target for HCC.http://www.sciencedirect.com/science/article/pii/S2405844023015141ARID1APrognosisHepatocellular carcinomaPrognostic biomarker |
| spellingShingle | Guang-Xiao Meng Chun-Cheng Yang Lun-Jie Yan Ya-Fei Yang Yu-Chuan Yan Jian-Guo Hong Zhi-Qiang Chen Zhao-Ru Dong Tao Li The somatic mutational landscape and role of the ARID1A gene in hepatocellular carcinoma Heliyon ARID1A Prognosis Hepatocellular carcinoma Prognostic biomarker |
| title | The somatic mutational landscape and role of the ARID1A gene in hepatocellular carcinoma |
| title_full | The somatic mutational landscape and role of the ARID1A gene in hepatocellular carcinoma |
| title_fullStr | The somatic mutational landscape and role of the ARID1A gene in hepatocellular carcinoma |
| title_full_unstemmed | The somatic mutational landscape and role of the ARID1A gene in hepatocellular carcinoma |
| title_short | The somatic mutational landscape and role of the ARID1A gene in hepatocellular carcinoma |
| title_sort | somatic mutational landscape and role of the arid1a gene in hepatocellular carcinoma |
| topic | ARID1A Prognosis Hepatocellular carcinoma Prognostic biomarker |
| url | http://www.sciencedirect.com/science/article/pii/S2405844023015141 |
| work_keys_str_mv | AT guangxiaomeng thesomaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT chunchengyang thesomaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT lunjieyan thesomaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT yafeiyang thesomaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT yuchuanyan thesomaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT jianguohong thesomaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT zhiqiangchen thesomaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT zhaorudong thesomaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT taoli thesomaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT guangxiaomeng somaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT chunchengyang somaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT lunjieyan somaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT yafeiyang somaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT yuchuanyan somaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT jianguohong somaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT zhiqiangchen somaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT zhaorudong somaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma AT taoli somaticmutationallandscapeandroleofthearid1ageneinhepatocellularcarcinoma |